MPS Pharmaa Limited Schedules Board Meeting on May 28, 2026 to Approve FY26 Audited Financial Results

1 min read Updated on 18 May 2026, 05:02 PM

Reviewed by

Suketu GScanX News Team

AI Summary

MPS Pharmaa Limited (formerly Advik Laboratories Limited) has scheduled a Board of Directors meeting on May 28, 2026, at 12:00 P.M. at its New Delhi corporate office to consider and approve audited financial results for the quarter and financial year ended March 31, 2026. The board will also consider the appointment of M/s Sanghi & Co., Chartered Accountants as Internal Auditor for FY 2026-27. The trading window for company shares remains closed until May 30, 2026, in compliance with SEBI insider trading regulations.

*this image is generated using AI for illustrative purposes only.

MPS Pharmaa Limited (formerly Advik Laboratories Limited) has notified BSE Limited and Ahmedabad Stock Exchange Limited of an upcoming Board of Directors meeting, scheduled for Thursday, May 28, 2026, at 12:00 P.M. at the company's corporate office at 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi – 110001. The intimation, dated May 18, 2026, was issued pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The board meeting has been convened to transact several key items of business. The following matters are scheduled for consideration:

Approval of the Audited Financial Results of the company for the quarter and financial year ended March 31, 2026
Approval of the Auditors' Report on the audited financial results for the quarter and financial year ended March 31, 2026
Consideration of the appointment of M/s Sanghi & Co., Chartered Accountants as the Internal Auditor of the company for FY 2026-27
Any other business with the permission of the Board

Key Meeting Details

The table below summarises the key details of the scheduled board meeting:

Parameter:	Details
Meeting Date:	Thursday, May 28, 2026
Meeting Time:	12:00 P.M.
Venue:	703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi – 110001
Results Period:	Quarter and Financial Year ended March 31, 2026
Regulatory Reference:	Regulation 29 & 33, SEBI (LODR) Regulations, 2015
Trading Window Closure:	Until May 30, 2026

Trading Window Closure

In accordance with BSE Circular no. LIST/COMP/01/2019-20 dated April 02, 2019, and the company's Code of Conduct for Prevention of Insider Trading framed pursuant to the SEBI (Prohibition of Insider Trading) Regulation, 2015, the trading window for dealing in the shares of the company is already closed for all Directors, Officers, Designated Employees, and their relatives. The trading window shall remain closed until May 30, 2026, in connection with the declaration of audited financial results for the quarter and financial year ended March 31, 2026.

The intimation was signed by Pooja Chuni, Company Secretary, on behalf of MPS Pharmaa Limited. The company's registered office and factory are located at 138, Roz-Ka-Meo Industrial Area, Sohna – 122103 (Distt. Mewat), Haryana.

How have MPS Pharmaa Limited's revenue and profitability trends evolved over FY 2026 compared to prior years, and what guidance might management provide for FY 2027?

What strategic rationale lies behind the company's rebranding from Advik Laboratories Limited to MPS Pharmaa Limited, and how might this repositioning affect its market presence and investor perception?

Following the appointment of M/s Sanghi & Co. as Internal Auditor, are there any anticipated changes to the company's internal controls or compliance framework that could impact operational efficiency?